Nkarta, Inc. (NASDAQ:NKTX) VP Sells $62,100.00 in Stock

Posted by on Jun 7th, 2022

Nkarta, Inc. (NASDAQ:NKTX – Get Rating) VP Ralph Brandenberger sold 4,140 shares of the business’s stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $15.00, for a total transaction of $62,100.00. Following the transaction, the vice president now owns 5,300 shares in the company, valued at approximately $79,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NKTX traded up $0.60 during midday trading on Tuesday, reaching $14.93. The company’s stock had a trading volume of 511,145 shares, compared to its average volume of 1,844,915. The stock’s 50-day moving average is $13.05 and its 200-day moving average is $12.47. The firm has a market capitalization of $492.84 million, a price-to-earnings ratio of -5.29 and a beta of -0.32. Nkarta, Inc. has a 1 year low of $7.55 and a 1 year high of $40.64.

Nkarta (NASDAQ:NKTX – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.08). Sell-side analysts anticipate that Nkarta, Inc. will post -2.59 earnings per share for the current year.

Several brokerages recently issued reports on NKTX. Raymond James boosted their price target on shares of Nkarta from $17.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday, April 26th. HC Wainwright boosted their price target on shares of Nkarta from $25.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, April 25th. Zacks Investment Research upgraded shares of Nkarta from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Tuesday, May 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Nkarta in a research report on Tuesday, March 29th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Nkarta presently has an average rating of “Buy” and a consensus target price of $52.33.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantbot Technologies LP lifted its position in Nkarta by 39.1% during the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock valued at $36,000 after purchasing an additional 900 shares during the period. Federated Hermes Inc. lifted its position in Nkarta by 735.3% during the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock valued at $54,000 after purchasing an additional 4,147 shares during the period. Wells Fargo & Company MN lifted its position in Nkarta by 37.9% during the second quarter. Wells Fargo & Company MN now owns 8,032 shares of the company’s stock valued at $254,000 after purchasing an additional 2,207 shares during the period. Two Sigma Investments LP bought a new position in Nkarta during the third quarter valued at approximately $239,000. Finally, Chicago Partners Investment Group LLC bought a new position in Nkarta during the fourth quarter valued at approximately $110,000. Hedge funds and other institutional investors own 74.19% of the company’s stock.

Nkarta Company Profile (Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Recommended Stories

Insider Buying and Selling by Quarter for Nkarta (NASDAQ:NKTX)

Want More Great Investing Ideas?

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.